All In Biotech

Drug Trial Radar · NCT07737106

Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)

A Randomized, Double-blind, Active-controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) in Adults Aged 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Aug 21, 2025

Primary completion

Sep 18, 2025

Study completion Feb 24, 2026

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, active-controlled Phase I clinical trial to evaluate the safety and immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) developed by Sinovac.

Conditions

  • Influenza

Interventions

  • Influenza Vaccine (Split Virion), Inactivated (High Dose)Biological

    A single 0.5 mL dose of the investigational high-dose split influenza virus vaccine will be administered by intramuscular (IM) injection into the deltoid muscle of the upper arm. Each dose contains 60 μg of hemagglutinin from each influenza virus strain used for the current influenza season.

  • Influenza Vaccine (Split Virion), InactivatedBiological

    A single 0.5 mL dose of the active control standard-dose split influenza virus vaccine will be administered by intramuscular (IM) injection into the deltoid muscle of the upper arm. Each dose contains 15 μg of hemagglutinin from each influenza virus strain used for the current influenza season.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse ReactionsTime frame: Day 0 to Day 28 after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Urad Middle Banner Center for Disease Control and Prevention

    Bayan Nur, Inner Mongolia, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.